Sergio Bracarda

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.

The New England journal of medicine · 18 december 2025

Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer:...

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 mei 2025

PROs bij cisplatine-ineligibele patiënten met urotheelcarcinoom

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 april 2024

Enfortumab vedotin met of zonder pembrolizumab bij cisplatine-ineligibel urotheelcarcinoom: EV-103 cohort K

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 september 2023

Continue enzalutamide na progressie op enzalutamide plus cabazitaxel bij mCRPC

The Lancet. Oncology · 2022-11

Ipatasertib plus abiraterone bij mCRPC: IPATential150 fase III

Lancet (London, England) · 10 juli 2021

Sarcomatoïd niercelcarcinoom: eerstelijns behandelopties meta-analyse

European journal of cancer (Oxford, England : 1990) · 2020-09

PROs van atezolizumab-bevacizumab versus sunitinib bij mRCC: IMmotion151 analyse

Clinical cancer research : an official journal of the American Association for Cancer Research · 1 juni 2020

Nivolumab-ipilimumab versus sunitinib bij mRCC: CheckMate 214 42-maanden update

The Lancet. Oncology · 2019-10

Atezolizumab plus bevacizumab versus sunitinib bij onbehandeld mRCC: IMmotion151 fase III

Lancet (London, England) · 15 juni 2019

Ipatasertib plus abiraterone bij mCRPC: IPATential150 fase II

Clinical cancer research : an official journal of the American Association for Cancer Research · 1 februari 2019

Nivolumab plus ipilimumab versus sunitinib bij gevorderd niercelcarcinoom: CheckMate 214

The New England journal of medicine · 5 april 2018

IMA901 multipeptide kankervaccin plus sunitinib versus sunitinib alleen bij gevorderd niercelcarcinoom

The Lancet. Oncology · 2016-11